Neuland Laboratories, founded in 1984 in Hyderabad, has spent forty years building a reputation as one of India’s most dependable manufacturers of active pharmaceutical ingredients. The company serves more than 950 customers across 80 countries — and has quietly transitioned from large-volume generic APIs to complex intermediates, custom manufacturing, and peptide synthesis.
When Neuland Laboratories began operations in 1984, the Indian pharmaceutical industry was still in its early chapters. The company started as an active pharmaceutical ingredient manufacturer — the kind of business where success is measured not in brand recognition among patients but in the consistency of what comes off the production line. APIs are the molecules that make medicines work, and the companies that make them well tend to be invisible to everyone except the formulators who depend on them.
For its first two decades, Neuland built its business on what the industry calls prime APIs — high-volume, well-established molecules supplied to generic drug manufacturers worldwide. The work was technically demanding but commercially straightforward: produce at scale, meet pharmacopeial specifications, pass regulatory inspections, and compete on reliability and cost. It was a model that rewarded operational discipline, and Neuland got very good at it.
By the early 2000s, the company had established a customer base spanning more than 80 countries and earned a reputation among global pharmaceutical firms as a supplier that delivered on specification and on time. That dependability — unglamorous as it sounds — became the foundation for everything that followed.
The global API market has a well-known problem: over time, margins on large-volume generic molecules compress as more manufacturers enter the field. Neuland recognised this dynamic earlier than most of its peers and began a deliberate shift toward higher-value work — custom development and manufacturing, or CDMO services, where the company synthesises molecules designed by its clients rather than producing its own catalogue of generics.
This transition required a different kind of chemistry and a different kind of relationship. CDMO work means collaborating with innovator pharmaceutical companies from the development stage through commercial-scale production. It demands process chemistry expertise, intellectual property discipline, and the ability to scale from kilograms to tonnes without losing purity or yield. Neuland invested in dedicated facilities for custom manufacturing, expanded its R&D capabilities, and built the regulatory track record needed for innovator companies to trust it with their proprietary molecules.
The results show in the revenue mix. What was once a company defined entirely by catalogue APIs now derives a significant and growing share of its income from custom synthesis and contract manufacturing — work that carries higher margins and longer customer relationships than commodity API sales.
The most telling indicator of where Neuland is headed is its investment in peptide synthesis. Peptides — short chains of amino acids used in treatments for diabetes, oncology, and metabolic disorders — represent one of the fastest-growing segments of pharmaceutical manufacturing. The chemistry is more complex than traditional small-molecule synthesis, the equipment is more specialised, and the number of companies globally that can produce peptide APIs at commercial scale is small.
Neuland’s decision to build peptide manufacturing capabilities was not a pivot away from its core business but an extension of the same logic that drove the CDMO transition: move toward work that is harder to do, harder to replicate, and therefore more durable. The company now offers both small molecule and peptide API manufacturing, positioning it to serve the next generation of pharmaceutical products alongside its established generic API business.
With 1,794 employees as of FY25 and operations headquartered in Hyderabad, Neuland remains mid-sized by industry standards. That is, in many ways, the point. The company has chosen depth over breadth — a focused portfolio of capabilities executed at a level of quality that keeps 950 customers coming back across four decades.
Sources: Neuland Laboratories Annual Reports FY2022 through FY2025. US FDA facility registration data.